TY - JOUR
T1 - The Japanese Epidemiologic Study for Perioperative Anaphylaxis, a prospective nationwide study
T2 - clinical signs, severity, and therapeutic agents
AU - Suigiyama, Yuki
AU - Takazawa, Tomonori
AU - Watanabe, Natsuko
AU - Bito, Kiyoko
AU - Fujiyoshi, Tetsuhiro
AU - Hamaguchi, Shinsuke
AU - Haraguchi, Takashi
AU - Horiuchi, Tatsuo
AU - Kamiya, Yoshinori
AU - Maruyama, Noboru
AU - Masumo, Hitoshi
AU - Nakazawa, Harumasa
AU - Nagumo, Kazuhiro
AU - Orihara, Masaki
AU - Sato, Jun
AU - Sekimoto, Kenichi
AU - Takahashi, Kenichiro
AU - Uchiyama, Mutsumi
AU - Takahashi, Kazunobu
AU - Yamaguchi, Masao
AU - Kawamata, Mikito
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/7
Y1 - 2023/7
N2 - Background: Diagnosis of perioperative anaphylaxis is difficult because of its non-specific and variable signs and symptoms. Therapeutic agents used to treat anaphylaxis and anaesthesiologist responses also vary depending on the case, which might affect outcomes; however, only a few studies have focused on these factors. Methods: This prospective study of perioperative anaphylaxis, a part of the Japanese Epidemiologic Study for Perioperative Anaphylaxis, investigated the clinical signs, its severity, therapeutic drugs, epinephrine administration, and anaesthesiologist responses in cases of perioperative anaphylaxis to assess trends and variability. Shock index was used to assess severity of cardiovascular collapse. Results: In 43 patients analysed in this study, cardiovascular signs (88.4%) were the most frequent, followed by skin (81.4%) and respiratory signs (60.5%). The presence of signs increased during the clinical course. The median time from the first signs to diagnosis of anaphylaxis was 10 (5.0–17.8) min. The rates of epinephrine use were 30.2% (unused), 48.8% (i.v.), and 20.9% (i.m.). The median time from diagnosis of anaphylaxis to epinephrine administration was 7 (inter-quartile range: 1.5–8.0) min. Antihistamines and corticosteroids were each used in 69.8% of cases. The worst shock index was higher in patients who received i.v. epinephrine (2.77 [0.90] mean [standard deviation]) than in both no epinephrine use cases (1.35 [0.41]) and i.m. epinephrine cases (1.89 [0.77] (P<0.001]). Conclusions: The clinical signs and treatments of perioperative anaphylaxis are variable, and the choice regarding epinephrine administration is based on symptom severity. Clinical trial registration: UMIN000035350.
AB - Background: Diagnosis of perioperative anaphylaxis is difficult because of its non-specific and variable signs and symptoms. Therapeutic agents used to treat anaphylaxis and anaesthesiologist responses also vary depending on the case, which might affect outcomes; however, only a few studies have focused on these factors. Methods: This prospective study of perioperative anaphylaxis, a part of the Japanese Epidemiologic Study for Perioperative Anaphylaxis, investigated the clinical signs, its severity, therapeutic drugs, epinephrine administration, and anaesthesiologist responses in cases of perioperative anaphylaxis to assess trends and variability. Shock index was used to assess severity of cardiovascular collapse. Results: In 43 patients analysed in this study, cardiovascular signs (88.4%) were the most frequent, followed by skin (81.4%) and respiratory signs (60.5%). The presence of signs increased during the clinical course. The median time from the first signs to diagnosis of anaphylaxis was 10 (5.0–17.8) min. The rates of epinephrine use were 30.2% (unused), 48.8% (i.v.), and 20.9% (i.m.). The median time from diagnosis of anaphylaxis to epinephrine administration was 7 (inter-quartile range: 1.5–8.0) min. Antihistamines and corticosteroids were each used in 69.8% of cases. The worst shock index was higher in patients who received i.v. epinephrine (2.77 [0.90] mean [standard deviation]) than in both no epinephrine use cases (1.35 [0.41]) and i.m. epinephrine cases (1.89 [0.77] (P<0.001]). Conclusions: The clinical signs and treatments of perioperative anaphylaxis are variable, and the choice regarding epinephrine administration is based on symptom severity. Clinical trial registration: UMIN000035350.
KW - anaphylaxis
KW - epinephrine
KW - perioperative anaphylaxis
KW - symptoms
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85151460993&partnerID=8YFLogxK
U2 - 10.1016/j.bja.2023.02.023
DO - 10.1016/j.bja.2023.02.023
M3 - 学術論文
C2 - 36967279
AN - SCOPUS:85151460993
SN - 0007-0912
VL - 131
SP - 170
EP - 177
JO - British Journal of Anaesthesia
JF - British Journal of Anaesthesia
IS - 1
ER -